Hyperkinetic movement disorders

Published on 19/03/2015 by admin

Filed under Pathology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 2428 times

30

Hyperkinetic movement disorders

Several clinical conditions are characterized by the presence of excessive uncontrolled movements and are grouped as hyperkinetic movement disorders. These are chorea and ballismus, myoclonus, and dystonia. Tics can also be classed as hyperkinetic disorders, though pathologic studies of the commonest type (Gilles de la Tourette syndrome) have not yet revealed significant histopathologic abnormalities.

CHOREA

Chorea is characterized by the presence of non-rhythmic rapid involuntary movements and can be divided into hereditary and sporadic groups.

image GENETICS AND BIOLOGY OF HUNTINGTON DISEASE (HD)

image HTT, the gene for HD, is subtelomeric on the short arm of chromosome 4 and codes for the protein huntingtin (HTT), which is widely expressed in fetal and adult tissues, but of unknown function. HTT includes a CAG repeat sequence in its N-terminal region. The normal gene contains 9–37 CAG repeats (each encoding glutamine); in HD the number of repeats ranges from 37 to 100 or more. Huntingtin is a very large protein predicted to consist mainly of repeated units of about 50 amino acids, termed HEAT repeats. These repeats are composed of two antiparallel α-helices with a helical hairpin configuration, which assemble into a superhelical structure with a continuous hydrophobic core (Fig. 30.1).

image The polyglutamine resulting from transcription of the CAG repeat has been shown to bind several other proteins. Proposed mechanisms contributing to pathology include loss of huntingtin function, and toxic gain of novel function(s). Nuclear aggregation has been proposed to cause transcriptional dysregulation, impair proteolysis, and stimulate apoptosis. The cellular functions of huntingtin are still not completely understood. The protein is mostly cytoplasmic, with membrane attachment via palmitoylation at cysteine. A putative nuclear export signal is present near the C-terminus but a clear nuclear localization signal has not been identified. HTT shuttles into the nucleus, has a role in vesicle transport, and can regulate gene transcription. It may also regulate RNA trafficking.

image Longer CAG repeats predict earlier onset and more rapid neurologic decline. However, there is up to 50–70% of variance in age of onset, due to modifying genes and the environment.

image HD, along with several other inherited neurological disorders caused by expansion of a CAG repeat, is classed as a polyglutamine disorder. Prevalence of HD is 4–10 per 100 000 in the western world, with many more people at risk of the disease. Mean age of onset is 40 years, death occurring 15–20 years from onset.

image The disease shows anticipation: later generations are affected at an earlier age and more severely than earlier generations in the same family. This phenomenon is associated with a progressive increase in the length of CAG repeat sequences as the disease is transmitted through successive generations. Very rare sporadic cases of HD are usually due to expansion of a 34–37 CAG repeat (intermediate allele) in an unaffected male patient.

HUNTINGTON DISEASE (HD)

HD causes chorea, rigidity, and cognitive decline leading to dementia. The incidence of this disease is 4–7/100 000 in most populations. It is an autosomal dominant condition with a variable age of onset:

MACROSCOPIC APPEARANCES

Cerebral atrophy is usually present (Fig. 30.3) with a reduction in brain weight of approximately 30%. This is associated with a 21–29% loss of volume of the cerebral cortex and a 29–34% loss of white matter. The most characteristic macroscopic abnormality is atrophy of the caudate nucleus, putamen, and globus pallidus (Fig. 30.4).

MICROSCOPIC APPEARANCES

The most marked histologic changes are seen in the basal ganglia where loss of neurons is associated with astrocytic gliosis in affected areas of the striatum (Fig. 30.5). In general, morphometric studies are required to show loss of large pyramidal neurons in the neocortex and hippocampus, which occurs in the absence of astrocytosis. Neuronal loss may also be found in the hypothalamus, substantia nigra, and cerebellar cortex, particularly in severe early-onset cases. The neuronal loss from the striatum preferentially affects certain neuronal subtypes.

The normal striatum has two neuronal compartments:

Spiny neurons are severely depleted in HD. Loss of aspiny neurons is much less marked and occurs in late stages of the disease.

Immunohistochemical staining for ubiquitin or huntingtin reveals pathological accumulation of huntingtin protein within intranuclear inclusion bodies or in neurites. Abnormal neurites have been shown to be widely distributed throughout the cortex in HD by immunostaining for ubiquitin. Intranuclear inclusions are found in cortical neurons (Fig. 30.6 and Table 30.1). However, inclusions tend to be numerous only in cases with a long expansion repeat and hence a younger age of onset. In late-onset cases associated with a short expansion nuclear inclusions may be sparse.

image

30.6 Patterns of huntingtin accumulation, revealed by labeling of polyglutamine repeats with the antibody 1 C2. The labeling may be diffuse, or aggregated into granules or discrete inclusions. Combinations of nuclear and cytoplasmic inclusions are occasionally seen.
The types of inclusions vary between different brain regions (see Table 30.1). (a) Diffuse nuclear, (b) aggregated nuclear (the aggregate is not in the nucleolus), (c) diffuse nuclear and cytoplasmic, and (d) granular, cytoplasmic-only inclusions. (e) Cytoplasmic inclusions in the cortex, (f) small aggregates in the neuropil, and (g) aggregates in oligodendrocytes of the subcortical white matter.

image CLINICAL PRESENTATION OF HUNTINGTON DISEASE (HD)

Peripheral abnormalities

Peripheral features of HD, such as weight loss and skeletal muscle wasting, are probably unrelated to the neurological dysfunction or general sickness. Huntingtin is expressed in many tissues and organs.

image Weight loss, beginning as minor loss in presymptomatic gene carriers and ending with profound cachexia in advanced disease. Correlates with CAG repeat number.

image Skeletal-muscle wasting, possibly due to defects caused by mutated huntingtin in myocytes.

image Cardiac failure. Leading cause of death in these patients. Autonomic nervous system involvement may contribute.

image Impaired glucose tolerance: insulin production reduced, altered gene transcription in islet cells.

image Leukocytes have altered gene transcription, and mitochondrial function. Adenosine A2A receptor function and monoamine oxidase activity are disrupted.

image Osteoporosis: severity correlates with the number of CAG repeats.

image Testicular atrophy. The highest levels of huntingtin expression are found in the brain and testes. men have reduced testosterone concentrations but fertility is unaffected.

(Adapted from van der Burg et al. 2009.)

NEUROACANTHOCYTOSIS

This term is applied to multisystem degenerative neurologic disorders, genetically heterogeneous, associated with acanthocytes in the blood. The two main neuroacanthocytosis syndromes are autosomal recessive chorea-acanthocytosis and X-linked McLeod syndrome. The latter is an X-linked disorder characterized by striatal degeneration and myopathy, occurring in association with the Kell blood group variant, in which the Kell blood group precursor protein, Kx, is lacking.

MACROSCOPIC AND MICROSCOPIC APPEARANCES

The main findings are atrophy, neuronal loss, and astrocytic gliosis in various brain regions (Fig. 30.7). Examination of a fresh blood film reveals acanthocytes. In some cases acanthocytes are not easy to find and repeat examination or scanning electron microscopy of blood may be necessary for diagnosis.

BALLISMUS AND HEMIBALLISMUS

Ballismus and hemiballismus are severe forms of chorea characterized by involuntary violent flinging movements of the limbs. Almost invariably this is caused by damage to the subthalamic nucleus (Fig. 30.9). The main causes are infarcts, small hemorrhages, infection, metastatic tumor, and demyelination. The neurochemical pathology is illustrated in Figure 30.10.

DYSTONIA

This is characterized by sustained muscle contractions that cause abnormal postures or twisting, repetitive movements. Dystonia can be primary, when disease is usually a monogenic disorder, or may be secondary to other disease processes (symptomatic). Primary dystonias are not usually associated with any gross neuropathological changes and represent functional disorders.

Primary dystonias can be grouped into three categories based on clinical features, as follows (Table 30.2):

Table 30.2

Primary dystonias

image

image INHERITED FORMS OF PRIMARY DYSTONIA

Dopa-responsive dystonia: Segawa syndrome (DYT5)

There is a paucity of data on the pathogenesis and neuropathology of primary dystonia. In the event of an autopsy, the brain and spinal cord should be preserved for morphologic, neurochemical and genetic analysis.

REFERENCES

Chorea

Cattaneo, E., Rigamonti, D., Goffredo, D., et al. Loss of normal huntingtin function: new developments in Huntington’s disease research. Trends Neurosci. 2001;24(3):182–188.

Danek, A., Jung, H.H., Melone, M.A., et al. Neuroacanthocytosis: new developments in a neglected group of dementing disorders. J Neurol Sci. 2005;229–230:171–186.

Davies, S.W., Turmaine, M., Cozens, B.A., et al. From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington’s disease. Philos Trans R Soc Lond B Biol Sci. 1999;354(1386):981–989.

DiFiglia, M., Sapp, E., Chase, K.O., et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 1997;277:1990–1993.

Herndon, E.S., Hladik, C.L., Shang, P., et al. Neuroanatomic profile of polyglutamine immunoreactivity in Huntington disease brains. J Neuropathol Exp Neurol. 2009;68(3):250–261.

Ishida, C., Makifuchi, T., Saiki, S., et al. A neuropathological study of autosomal-dominant chorea-acanthocytosis with a mutation of VPS13A. Acta Neuropathol (Berl). 2009;117(1):85–94.

Jackson, M., Gentleman, S., Lennox, G., et al. The cortical neuritic pathology of Huntington’s disease. Neuropathol Appl Neurobiol. 1995;21:18–26.

Langbehn, D.R., Brinkman, R.R., Falush, D., et al. A new model for prediction of the age of onset and penetrance for Huntington’s disease based on CAG length. Clin Genet. 2004;65(4):267–277.

Li, H., Li, S.H., Johnston, H., et al. Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. Nat Genet. 2000;25(4):385–389.

McFarland, K.N., Cha, J.H. Molecular biology of Huntington’s disease. Handb Clin Neurol. 2011;100:25–81.

Raymond, L.A., André, V.M., Cepeda, C., et al. Pathophysiology of Huntington’s disease: time-dependent alterations in synaptic and receptor function. Neuroscience. 2011;198:252–273.

Rinne, J.O., Daniel, S.E., Scaravilli, F., et al. Nigral degeneration in neuroacanthocytosis. Neurology. 1994;44:1629–1632.

Ross, C.A., Tabrizi, S.J. Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10(1):83–98.

Schneider, S.A., Bhatia, K.P. Huntington’s disease look-alikes. Handb Clin Neurol.. 2011;100:101–112.

Stevenson, V.L., Hardie, R.J. Acanthocytosis and neurological disorders. J Neurol. 2001;248(2):87–94.

van der Burg, J.M., Bjorkqvist, M., Brundin, P. Beyond the brain: widespread pathology in Huntington’s disease. Lancet Neurol.. 2009;8(8):765–774.

Vonsattel, J.P. Huntington disease models and human neuropathology: similarities and differences. Acta Neuropathol (Berl).. 2008;115(1):55–69.

Vonsattel, J.P., Keller, C., Cortes Ramirez, E.P. Huntington’s disease – neuropathology. Handb Clin Neurol. 2011;100:83–100.

Vonsattel, J.P., Myers, R.H., Stevens, T.J., et al. Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol. 1985;44(6):559–577.

Waelter, S., Boeddrich, A., Lurz, R., et al. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol Biol Cell. 2001;12(5):1393–1407.

Walker, R.H., Jung, H.H., Danek, A. Neuroacanthocytosis. Handb Clin Neurol. 2011;100:141–151.

Walker, R.H., Jung, H.H., Dobson-Stone, C., et al. Neurologic phenotypes associated with acanthocytosis. Neurology. 2007;68(2):92–98.